“CURRENT UPDATES ON DIAGNOSTIC METHODS AVAILABLE FOR COVID-19 INFECTION”

PDF

Published: 2020-11-24

Page: 36-46


POOJAKUMARI VINAY SHUKLA

Department of Biotechnology, Veer Narmad South Gujarat University, Surat, India.

VIJAY J. UPADHYE *

Department of Microbiology, Parul Institute of Applied Sciences (PIAS), Parul University, Vadodara, India.

*Author to whom correspondence should be addressed.


Abstract

The abrupt pandemic set off by the novel coronavirus 2019 (COVID-19) has caused severe chaos among people worldwide. ‘‘SARS-CoV2’’, a previously unknown strain of coronaviruses caused a severe respiratory disease called Coronavirus disease (COVID-19) which emerged from Wuhan city of China on 30 December 2019 and declared as Universal health problem by the World Health Organisation in a month.  COVID-19 has created panic, and scientists are urged to test the efficiency and safety of drugs used to treat this disease. Various diagnostic kits to test for COVID-19 are available, and repurposing therapeutics for COVID-19 has shown to be clinically effective). In the analytic stage, real-time reverse transcription-PCR (RT-PCR) assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the post-analytical stage, testing results should be cautiously interpreted using both molecular and serological findings. This review discusses the updates on specimens/samples and recent efficient diagnostics to control the disease. It covers the latest issues and challenges for the laboratory diagnosis of infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Keywords: COVID-19, diagnostics; SARS-CoV-2, RT-PCR, biosensor, Convalescent plasma (CP).


How to Cite

SHUKLA, POOJAKUMARI VINAY, and VIJAY J. UPADHYE. 2020. “‘CURRENT UPDATES ON DIAGNOSTIC METHODS AVAILABLE FOR COVID-19 INFECTION’”. UTTAR PRADESH JOURNAL OF ZOOLOGY 41 (19):36-46. https://mbimph.com/index.php/UPJOZ/article/view/1731.